A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction—and help people who already have one, a new study shows.

A study has found that GLP-1 class obesity treatments, such as Wegovy and Mounjaro, may reduce the risk of alcohol or ...

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.

The protective effect was seen across a wide variety of addictive and habit-forming substances, including cocaine, opioids, alcohol, nicotine and cannabis.

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the year in 2025. Ozempic isn’t the only drug that mimics the natural GLP-1 ...

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think about obesity, diabetes and weight loss. Headlines often describe them as ...

Blockbuster GLP-1 drugs such as Ozempic and Mounjaro are perhaps the most effective drugs ever developed for type 2 diabetes and obesity. And although they arent yet approved by the U.S. Food and Drug ...

What to know about the side effects of GLP-1 drugs, Ozempic, Wegovy, Mounjaro With class action lawsuits filed, these are the alleged side effects of GLP-1 drugs, like Ozempic, Wegovy and Mounjaro.